Skip to content
Recall Observatory FDA recall evidence

Drug product

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56

D-0517-2017

February 07, 2017

Class II

Product summary

Firm
Teva Pharmaceuticals USA
Event
Event 76432
Status
Terminated
Classification
Class II
Quantity
7,628 HDPE bottles (228,840 tablets)
Official record key
drug-enforcement:D-0517-2017

Official wording

Reason: Failed Impurities/Degradation Specifications

Code information: Lot 30227056A; Exp. 03/17

Distribution pattern: Nationwide

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    Failed Impurities/Degradation Specifications